Neogen SA
Neogen reported total assets of €17.8m at the end of the 2025 financial year (annual accounts filed with the NBB on 27 Oct 2026).
The score of Neogen shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +142 % Total assets +60 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Neogen's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Oct 2026
- Year ended 31 Dec 2024filed on 25 Sep 2025
- Year ended 31 Dec 2023filed on 09 Jul 2024
- Year ended 31 Dec 2022filed on 29 Aug 2023
- Year ended 31 Dec 2021filed on 05 Jul 2022
Neogen's financial analysis
- Solvency79.3%sector median: 41.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Neogen
Neogen's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0445.922.856
- VAT number
- BE0445922856
- Peppol
- Registered · 0208:0445922856 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 09 Dec 1991
- Registered office
- 1070 Anderlecht
- Latest accounts
- 2025 · filed on 27 Oct 2026
- Activity
- Manufacture of medicaments (NACE 21201)
Neogen (SA) has been based in Anderlecht since 1991, active in: manufacture of medicaments. For 2025, it reports a net profit of €2.39m and equity of €14.1m; its revenue is not published. Its solvency stands at 79.3%, above the median of its sector (41.4%).
Companies similar to Neogen
Companies in the same business, of comparable size and area, outside its group.
- Conforma Manufacture of pharmaceutical preparations Destelbergen · balance sheet €16.3m
- Will - Pharma Manufacture of pharmaceutical preparations Wavre · balance sheet €9.73m
- S.A. Laboratoires Pharmaceutiques Trenker Manufacture of basic pharmaceutical products Nivelles · balance sheet €16.1m
- KELA - Kempisch Laboratorium - Kela Laboratoria Manufacture of pharmaceutical preparations Hoogstraten · balance sheet €63.2m
- Upjohn Manufacture of pharmaceutical preparations Hoeilaart · balance sheet €12.3m
- Labo Phytophar Manufacture of condiments and seasonings Oostkamp · balance sheet €10.9m
- BePharBel Manufacturing Manufacture of basic pharmaceutical products Courcelles · balance sheet €27.4m
- Tilman Manufacture of pharmaceutical preparations Somme-Leuze · balance sheet €43.2m
Frequently asked questions about Neogen
What is the revenue of Neogen?
Neogen files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Neogen?
In Belgium, the VAT number is the company number prefixed with BE: BE0445922856 for Neogen, if the company is VAT-registered. Its company number (CBE) is 0445.922.856.
Where is the registered office of Neogen?
According to the CBE register, the registered office of Neogen is in 1070 Anderlecht.
What is the equity of Neogen?
At the close of the 2025 financial year, the equity of Neogen amounts to 14,074,430 €, a solvency of 79.3% of total assets.
Who manages Neogen?
The register lists 5 active mandates at Neogen. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Neogen
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →